Valeant Pharmaceuticals International Inc. (TSX:VRX). Pharmaceutical. Up 70 cents, or 4.75 per cent, to $15.43 on 2.4 million shares. Valeant has signed a deal to sell its Sprout Pharmaceuticals subsidiary to the company's former owners, two years after buying it for $1 billion in cash. Under the deal, Valeant will receive a six per cent royalty on sales of the female sexual health drug Addyi starting 18 months from the signing of the sale agreement. The agreement also ends a legal dispute between Sprout's former owners and Valeant.